Ссылки
(Расшифровка аббревиатур см. далее)
1. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB. High glycemic index foods, overeating, and obesity. Pediatrics 1999;103:656.
2. Drewnowski A., Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 1992;51:371-9.
3. Shah NP. Effects of milk-derived bioactives: an overview. Br J Nutr 2000;84(suppl1): S3-S10.
1. Drewnowski A., Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 1992;51:371-9.
2. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatr 2001;49:914-21.
3. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet 2001;357:354-7.
4. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, CourtJA. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the Al allele. Pharmacogenetics 1997;7:479-84.
5. Noble EP. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry 2000;15:79–89.
6. Noble EP, St. Jeor ST, Ritchie T, Syndulko K, St. Jeor SC, Fitch RJ, Brunner RL, Sparkes RS. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994a;42:257-60.
7. Noble EP, Noble RE, Ritchie T, Syndulko K, Bohlman MC, Noble LA, Zhang Y, Sparkes RS, Grandy DK. D2 dopamine receptor gene and obesity. Int] Eating Disord 1994b;15:205-17.
8. Stahl SM. The psychopharmacology of sex, part 1: neurotransmitters and the 3 phases of the human sexual response. J Clin Psychiatry 2001; 62:80-1.
9. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, et al. Case- control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 1998;90:358-63.
10. Knowler WC, Barrett-Conner E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl] Med 2002;346:393–403.
1. Blass EM, Camp CA. The ontogeny of face recognition: eye contact and sweet taste induce face preference in 9- and 12-week-old human infants. Devel Psychol 2001;37:762-74.
2. Brink PJ. Addiction to sugar. West] Nurs Res 1993;15:280-1.
3. Smith BA, Fillion TJ, Blass EM. Orally mediated sources of calming in 1-to 3-day-old infants. Devel Psychol 1990;26:731-7.
4. Blass EM, Ciaramitaro V. Oral determinants of state, affect, and action in new-born humans. Monogr Soc Res Child Dev 1994;59:1-96.
5. Morley JE, Levine AS, Yamada T, et al. Effect of exorphins on gastrointestinal function, hormonal release, and appetite. Gastroenterology 1983;84:1517-23.
6. Fukudome S, Yoshikawa M. Gluten exorphin C: A novel opioid peptide derived from wheat gluten. FEBS Lett 1993 Jan 18;316(1):17-9.
7. Dohan FC. Genetic hypothesis of idiopathic schizophrenia: its exorphin connection. Schizophr Bull 1988;14:489-94.
1. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, and Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 1992;51:371–379.
2. Pennington JAT. Bowes and Church’s Food Values of Portions Commonly Used, Seventeenth Edition (Philadelphia: Lippincott-Raven, 1998), p.383.
3. Koehler PE, Eitenmiller RR. High pressure liquid chromatographic analysis of tyramine, phenylethylamine and tryptamine in sausage, cheese, and chocolate. J of Food Sci 1978;43:1245-7.
4. Hurst WJ, Martin RA, Zoumas, BL. Biogenic amines in chocolate: a review. Nutr Rep Intl 1982;26:1081-6.
5. di Tomaso E, Beltramo M, Piomelli D. Brain cannabinoids in chocolate. Nature 1996;382:677-8.
6. Tuomisto T, Hetherington MM, Morris MF, Tuomisto MT, Turjanmaa V, Lappalainen R. Psychological and physiological characteristics of sweet food "addiction." Int] Eat Disord 1999;25:169-75.
7. Michener W, Rozin P. Pharmacological versus sensory factors in the satiation of chocolate craving. Physiol Behav 1994; 56:419-22.
8. Macdiarmid JI, Hetherington MM. Mood modulation by food: an exploration of affect and cravings in "chocolate addicts." Br] Clin Psychol l995;34:129-38.
9. Drewnowski A. Taste preferences and food intake. Annu Rev Nutr 1997;17: 237-53.
10. Michell GF, Mebane AH, Billings CK. Effect of bupropion on chocolate craving. Am] Psychiatry 1989;146:119-20.
11. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000 May;61(5):368-72.
1. Hazum E, Sabatka JJ, Chang KJ, Brent DA, Findlay JWA, Cuatrecasas P. Morphine in cow and human milk: Could dietary morphine constitute a ligand for specific morphine (μ) receptors? Science 1981;213:1010-2.
2. Benyhe S. Morphine: new aspects in the study of an ancient compound. Life Sci 1994;55:969-79.
3. Meisel H, FitzGerald RJ. Opioid peptides encrypted in intact milk protein sequences. Br] Nutr 2000;84(suppll):S27-S31.
4. Panksepp J, Normansell L, Siviy S, Rossi J, Zolovick AJ. Casomorphins reduce separation distress in chicks. Peptides 1984;5:829-31.
5. Shah NP. Effects of milk-derived bioactives: an overview. Br] Nutr 2000;84 (suppll):S3-S10.
6. Meisel H. Chemical characterization of opioid activity of an exorphin isolated from in vivo digests of casein. FEBS Letters 1986;196:223-7.
7. Teschemacher H, Umbach M, Hamel U, et al. No evidence for the presence of β-casomorphin in human plasma after ingestion of cows' milk or milk products. J Dairy Res 1986; 53:135-8.
8. Umbach M, Teschemacher H, Praetorius K, Hirschhäuser R, Bostedt H. Demonstration of a β-casomorphin immunoreactive material in the plasma of newborn calves after milk intake. Regulatory Peptides 1985;12:223-30.
9. Chabance B, Marteau P, Rambaud JC, Migiiore-Samour D, Boynard M, Perrotin P, Guillet R, Jollés P, Fiat AM. Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochimie 1998;80:155-65.